Nexplanon Does NOT Significantly Increase DVT/PE Risk
Nexplanon (etonogestrel implant) is NOT associated with a clinically significant increased risk of DVT or PE, unlike combined hormonal contraceptives containing estrogen. This progestin-only contraceptive appears to be among the safest hormonal contraceptive options regarding venous thromboembolism risk.
Evidence-Based Risk Assessment
Progestin-Only Contraceptives Show Minimal VTE Risk
The most recent guidelines clearly distinguish between combined hormonal contraceptives (containing estrogen + progestin) and progestin-only methods like Nexplanon. Progestin-only pills and hormone-releasing intrauterine devices are NOT associated with significant VTE risk increases 1. The 2019 ESC Guidelines explicitly state that "hormone-releasing intrauterine devices and some progesterone-only pills (used at contraceptive doses) are not associated with a significant increase in VTE risk" and are "often proposed to women with a personal or strong family history of VTE" 1.
The French Society of Endocrinology guidelines (2012) provide specific data: progestin-only contraceptives showed no excess VTE risk with levonorgestrel, norethisterone, or desogestrel formulations 2. A meta-analysis found an odds ratio of only 1.45 (95% CI: 0.92-2.26) for progestin-based contraception overall, which was not statistically significant 2.
Research Data on Etonogestrel Implants
The 2012 Danish cohort study of 1.6 million women provides the most robust data on Nexplanon specifically. Subcutaneous implants (which include Nexplanon) showed a relative risk of only 1.4 (95% CI: 0.6-3.4) compared to non-users—this was NOT statistically significant 3. This contrasts sharply with transdermal patches (RR 7.9) and vaginal rings (RR 6.5), which showed dramatically elevated risks.
FDA Label Acknowledges Uncertainty But Reports Events
The Nexplanon FDA label states: "It is unknown whether this increased risk [seen with combined hormonal contraceptives] is applicable to etonogestrel alone" 4. However, it does note postmarketing reports of thrombotic events including "pulmonary emboli (some fatal), deep vein thrombosis, myocardial infarction, and strokes" in women using etonogestrel implants 4.
Critical context: Postmarketing reports do not establish causation. The 2025 case report 5 describes a VTE after Nexplanon insertion, but this patient had multiple high-risk factors (severe pre-eclampsia, gestational diabetes, recent C-section, immediate postpartum period)—any of which independently increases VTE risk substantially.
Clinical Decision-Making Algorithm
When Nexplanon is APPROPRIATE (Low VTE Concern):
- Women with personal or family history of VTE seeking contraception
- Women with inherited thrombophilias who need contraception
- Women who cannot use estrogen-containing contraceptives
- Standard contraceptive candidates without specific VTE risk factors
When to Exercise CAUTION (Not Contraindicated, But Assess):
- Immediate postpartum period: The FDA label recommends not using Nexplanon before 21 days postpartum due to the inherently high VTE risk in this period 4
- Active thrombosis: Remove Nexplanon if thrombosis occurs 4
- Long-term immobilization: Consider removal for prolonged immobilization from surgery or illness 4
- History of thromboembolic disorders: Counsel about recurrence possibility, though Nexplanon itself adds minimal risk 4
Risk Stratification Specifics:
The U.S. Medical Eligibility Criteria (2024) classifies implants as Category 1 (no restriction) for most VTE risk factors, including history of DVT/PE, current DVT/PE on anticoagulation, major surgery with prolonged immobilization, and known thrombophilias 6. This is the most permissive classification possible.
Key Clinical Pitfalls to Avoid
Don't confuse combined hormonal contraceptives with progestin-only methods: The 2-6 fold VTE risk increase applies to estrogen-containing contraceptives 1, NOT to Nexplanon.
Don't attribute postpartum VTE to Nexplanon: The postpartum period itself carries a 60-fold increased VTE risk 5. Timing coincidence does not equal causation.
Don't overlook other VTE risk factors: Obesity, smoking, age >40, cancer, immobilization, and inherited thrombophilias are the actual drivers of VTE risk 7, 1.
Don't delay appropriate contraception in high-risk women: For women who cannot use estrogen-containing methods due to VTE risk, Nexplanon is one of the safest and most effective options available.
Comparative Context
Combined oral contraceptives increase VTE risk 3-fold overall, with third-generation pills (containing desogestrel/gestodene) showing rates of 1-2 per 10,000 women per year 7. Vaginal rings and patches show even higher risks (6.5-7.9 fold) 3. Nexplanon's risk profile is fundamentally different and substantially lower.